{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T22:48:08Z","timestamp":1781563688880,"version":"3.54.5"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>This study aimed to evaluate the impact of combining high-intensity statins with CETP inhibitors on lipid levels, as well as to explore their potential clinical significance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a comprehensive search of relevant studies in the PubMed, Embase, Cochrane Library, and Web of Science databases. The Cochrane Risk of Bias Tool RoB 2.0 was employed to evaluate the quality of the included studies. Statistical analyses were carried out using STATA 15 software, with primary outcomes being high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Out of 2,552 records, 7 studies were included in the final analysis. The findings revealed that the combination of high-intensity statins with CETP inhibitors significantly raised HDL-C levels (SMD 2.47 [1.77, 3.18], p &amp;lt; 0.001) and lowered LDL-C levels (SMD -1.75 [-2.19, -1.31], p &amp;lt; 0.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Compared to statin monotherapy, the combination of high-intensity statins and CETP inhibitors resulted in a more pronounced increase in HDL-C and ApoAI, while reducing LDL-C, triglycerides (TG), and ApoB levels, without increasing the incidence of adverse events.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1512670","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T04:14:47Z","timestamp":1746072887000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Lipid-lowering effect of combined therapy with high-intensity statins and CETP inhibitors: a Systematic Review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Liubo","family":"Xiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingchun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.16412","article-title":"Hyperlipidemia: A review of the novel methods for the management of lipids","volume":"13","author":"Ezeh","year":"2021","journal-title":"Cureus"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.6.6642-1","article-title":"Hyperlipidemia: diagnostic and therapeutic perspectives","volume":"85","author":"Ballantyne","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Di Angelantonio","year":"2009","journal-title":"Jama"},{"key":"B5","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12944-023-01908-x","article-title":"A cross-sectional study exploring the relationship between the dietary inflammatory index and hyperlipidemia based on the National Health and Nutrition Examination Survey (2005-2018)","volume":"22","author":"Han","year":"2023","journal-title":"Lipids Health Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000022887","article-title":"Suboptimal management of hypertriglyceridemia in the outpatient setting is associated with the recurrent pancreatitis: A retrospective cohort study","volume":"99","author":"Yan","year":"2020","journal-title":"Medicine"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s1262-3636(07)70061-7","article-title":"Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease","volume":"29","author":"Diraison","year":"2003","journal-title":"Diabetes Metab"},{"key":"B8","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1542\/pir.2019-0053","article-title":"Hyperlipidemia","volume":"41","author":"Stewart","year":"2020","journal-title":"Pediatr review"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.9.1132","article-title":"High-intensity statin treatment for coronary heart disease","volume":"291","author":"Sacks","year":"2004","journal-title":"Jama"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/HCO.0000000000000839","article-title":"Triglyceride-rich lipoproteins, apolipoprotein C-III, angiopoietin-like protein 3, and cardiovascular events in older adults: Atherosclerosis Risk in Communities (ARIC) study","volume":"29","author":"Hussain","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R082735","article-title":"Cholesteryl ester transfer protein and its inhibitors","volume":"59","author":"Shrestha","year":"2018","journal-title":"J Lipid Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2021.03.016","article-title":"Pathophysiology and inhibition of cholesteryl ester transfer protein for prevention of cardiovascular diseases: An update","volume":"26","author":"Banerjee","year":"2021","journal-title":"Drug Discov Today"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab718","article-title":"Combination lipid-lowering therapy as first-line strategy in very high-risk patients","volume":"43","author":"Ray","year":"2022","journal-title":"Eur Heart J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Systematic Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000625","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: A report of the american college of cardiology\/american heart association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.P026328","article-title":"Relationship between atorvastatin dose and the harm caused by torcetrapib","volume":"53","author":"Barter","year":"2012","journal-title":"J Lipid Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2010.509342","article-title":"No clinically relevant drugdrug interactions when dalcetrapib is co-administered with atorvastatin","volume":"19","author":"Derks","year":"2010","journal-title":"Expert Opin Investigational Drugs"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009358709","article-title":"Coadministration of dalcetrapib with pravastatin, rosuvastatin, or simvastatin: No clinically relevant drug-drug interactions","volume":"50","author":"Derks","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.121.317181","article-title":"Pharmacological inhibition of CETP (Cholesteryl ester transfer protein) increases HDL (High-density lipoprotein) that contains apoC3 and other HDL subspecies associated with higher risk of coronary heart disease","volume":"42","author":"Furtado","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa071359","article-title":"Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia","volume":"356","author":"Kastelein","year":"2007","journal-title":"New Engl J Medicine"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01936-7","article-title":"Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial","volume":"28","author":"Nicholls","year":"2022","journal-title":"Nat Medicine"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2017.04.008","article-title":"Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial","volume":"261","author":"Nicholls","year":"2017","journal-title":"Atherosclerosis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2023.02.003","article-title":"The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint Clinical Perspective from the National Lipid Association and the American Society for Preventive Cardiology","volume":"17","author":"Virani","year":"2023","journal-title":"J Clin Lipidol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2174\/0115734099292078240218095540","article-title":"Chemical synthesis, biological evaluation, and cheminformatics analysis of a group of chlorinated diaryl sulfonamides: promising inhibitors of cholesteryl ester transfer protein","author":"Abu Khalaf","year":"2024","journal-title":"Curr computer-aided Drug design"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-023-01087-1","article-title":"Structure-based mechanism and inhibition of cholesteryl ester transfer protein","volume":"25","author":"Xue","year":"2023","journal-title":"Curr Atheroscler Rep"},{"key":"B27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11883-023-01184-1","article-title":"Obicetrapib: reversing the tide of CETP inhibitor disappointments","volume":"26","author":"Kastelein","year":"2024","journal-title":"Curr Atheroscler Rep"},{"key":"B28","doi-asserted-by":"publisher","first-page":"981","DOI":"10.3390\/nu5030981","article-title":"Hypertriglyceridemia","volume":"5","author":"Brahm","year":"2013","journal-title":"Nutrients"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2024.2444986","article-title":"Advances in the pharmacological management of hyperlipidemia through the use of combination therapies","volume":"26","author":"Wierzbicki","year":"2025","journal-title":"Expert Opin Pharmacother"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000179009.60612.28","article-title":"Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia","volume":"25","author":"Bisoendial","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.06.067","article-title":"Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels","volume":"48","author":"Davidson","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000015857.31889.7B","article-title":"Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study","volume":"105","author":"de Grooth","year":"2002","journal-title":"Circulation"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2008.06.022","article-title":"Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia","volume":"123","author":"Hermann","year":"2009","journal-title":"Thromb Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and cardiovascular outcomes in high-risk vascular disease","volume":"376","author":"Lincoff","year":"2017","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1346152","article-title":"The impact of SLCO1B1 rs4149056 on LDL-C target achievement after lipid lowering therapy optimization in men and women with familial hypercholesterolemia","volume":"15","author":"Bosco","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3390\/jcdd11050152","article-title":"Cholesteryl ester transfer protein inhibitors and cardiovascular outcomes: A systematic review and meta-analysis","volume":"11","author":"Rehman","year":"2024","journal-title":"J Cardiovasc Dev Dis"},{"key":"B38","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jacl.2023.05.098","article-title":"Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial","volume":"17","author":"Ballantyne","year":"2023","journal-title":"J Clin Lipidol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60158-1","article-title":"Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidemia (TULIP): a randomized, double-blind, placebo-controlled phase 2 trial","volume":"386","author":"Hovingh","year":"2015","journal-title":"Lancet"},{"key":"B40","doi-asserted-by":"publisher","first-page":"9417","DOI":"10.3390\/ijms23169417","article-title":"Cholesteryl ester transfer protein inhibition reduces major adverse cardiovascular events by lowering apolipoprotein B levels","volume":"23","author":"Nelson","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.jacl.2016.06.006","article-title":"Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses","volume":"10","author":"van Capelleveen","year":"2016","journal-title":"J Clin Lipidol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000219695.84644.56","article-title":"Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans","volume":"26","author":"Millar","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.5551\/jat.64828","article-title":"Obicetrapib as an adjunct to stable statin therapy in Japanese subjects: results from a randomized phase 2 trial","volume":"31","author":"Harada-Shiba","year":"2024","journal-title":"J Atheroscler Thromb"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2014.02.018","article-title":"LDL cholesterol performance of beta quantification reference measurement procedure","volume":"431","author":"Nakamura","year":"2014","journal-title":"Clinica chimica acta; Int J Clin Chem"},{"key":"B46","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1512670\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T04:14:49Z","timestamp":1746072889000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1512670\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":46,"alternative-id":["10.3389\/fendo.2025.1512670"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1512670","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,1]]},"article-number":"1512670"}}